Abstract: The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

Abstract: The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

Abstract: The present invention provides an image processing method to assess quantitative myocardial blood flow and/or myocardial flow reserve, comprising the steps of: (a) pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) optionally, denoising to improve the quality of image, (iii) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity, (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/k2) to stabilize and improve estimation of K1, k2 and total blood volume (TBV) and subsequent myocardial blood flow measures, and (v) data normalization by dividing by the maximum of the blood input function; (b) assessing the individual signals pre-processed in step (a) in order to generate K1 and TBV parametric maps using artificial neural network; (c) post-processing of K1, k2 and TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocardi

Abstract: The present invention describes methods and techniques to improve scintigraphic images obtained by using nuclear medicine techniques for diagnostic analysis. The present invention describes a method and technique to up-sample and down-sample nuclear medicine images that models photon counts and noise characteristics of an image at its target resolution.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: A radioisotope elution system is provided that has a component in a cabinet with a door equipped with an authentication system to open. The system may also have a user interface equipped with an authentication system. The radioisotope elution system has a dose calibrator equipped with a lifting mechanism for lifting and/or lowering the vial to be tested in the dose calibrator. The lifting mechanism may be controlled for preventing the vial from being lifted during a quality control test on a sample of eluate in the vial. This feature prevents a user from tampering and/or interfering with the vial while a quality control testing is in progress. There also is provided a radioisotope elution system with a scanning system for entering information about the radioisotope generator and/or the patient in the system. Systems ensuring that the eluant reservoir contains a saline solution are proposed.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe.

Abstract: The present invention provides a conjugate compound comprising a nanoparticulated enhanced permeability and retention (EPR) agent, which is an albumin, conjugated with one or more chelating agents, one or more target specific ligands and one or more detectable agents and optionally comprising one or more heterobifunctional crosslinkers and one or more pharmaceutically acceptable therapeutic agents. Further, the present invention provides a radiopharmaceutical composition and a kit comprising the said conjugate and also provides application of the same in diagnosis and therapy of various disease like cancer.

Abstract: Provided are systems for filling containers with radioactive and/or other types of potentially hazardous materials. In some aspects, the systems include a shielding material that substantially defines a chamber and, preferably, substantially blocks radioactivity, a conduit extending from outside to into the chamber, and a unit that is disposed in the chamber proximal to the conduit and is adapted to receive a capsule through the conduit. The systems of the present disclosure can further comprise a syringe, a syringe controller that is disposed in the dispensing chamber and adapted to meter an aliquot from a radioactive stock solution and inject the aliquot into the capsule or a vial.

Abstract: The present invention provides a radioisotope generator system with enhanced safety features and implements such system. In particular, the present invention provides a radioisotope generator system comprising a surface that comprises three ports: an evacuation port, a loading port, and a saline flush port. The saline flush port is permanently connected with the loading port so that the rinsing solution can be placed on the saline port and pass it through the Mo-99 vial to minimize the wastage of the Mo-99. The present invention provides a robust design of the three-port radioisotope generator, which is cost-effective and ensures improved safety from needle contamination.

Abstract: The present invention provides a method of diagnosing and/or treating a peripheral arterial disease (PAD) via Positron Emitting Tomography (PET) imaging technology. The invention provides artificial intelligence dose calculation, infusion or dose monitoring, image analysis, assessment and providing a severity score based on the image analysis and providing suitable therapy options for the subject diagnosed or at a risk of developing peripheral arterial disease.

Abstract: The present invention provides a closed loop generation and/or infusion system comprising a radionuclide generator, an activity detector, a controller, a dose calibrator, a pump, eluant source and an automated elution system controlled by software and hardware for generation and infusion of a radionuclide for administering a dose of generated radionuclide into a subject for diagnosing a peripheral arterial disease in a subject suffering from or suspected of suffering from peripheral arterial disease and/or metabolic disease via Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies.

Abstract: Disclosed herein are rubidium elution systems comprising a primary assembly including a 82Sr/82Rb generator, an activity detector, a waste container, a pump system, a sensor, a tubing circuit, at least one valve, and a computer; and a dose calibrator outside the primary assembly. The system may have an interface for configuring the dose calibrator, and a locking means for preventing access to the interface and reconfigurations of its parameters. Moreover, the dose calibrator may be in electronic communication with the computer of the system. Furthermore, the electronic communication can be embodied with an electronic cable having a breakaway connector. Also, the dose calibrator may be positioned on a mobile platform.

Abstract: A radioisotope elution system is provided, that has at least a component comprised in a cabinet and accessible via a door equipped with an authentication system to ensure safety. The system may also have a user interface equipped with an authentication system. It is also provided a radioisotope elution system that has a dose calibrator equipped with a lifting mechanism for lifting and/or lowering the vial to be tested in the dose calibrator. Advantageously, the lifting mechanism may be controlled for preventing the vial from being lifted during a quality control test on a sample of eluate in the vial. This feature prevents a user from tampering and/or interfering with the vial while a quality control testing is in progress. In another feature, there is provided a radioisotope elution system with a scanning system for entering information about the radioisotope generator and/or the patient in the system. Systems ensuring that the eluant reservoir contains a saline solution are proposed.

Abstract: The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

Abstract: The present invention relates to a medical radioisotope transport system that securely holds the radiopharmaceutical imaging system or medical elution system to the floor of a vehicle and ensures the protection of the elution system during transportation. The transport system as per the present invention includes at least a floor-mounting device, a support mechanism with transportation plates, and a locking device. The transport system as per the present invention is encompassed with advanced technical and safety features to ensure safe transportation of radiopharmaceuticals ensuring compliance to the regulatory and quality requirements. The transport system as per the present invention is easy to use, and successfully overcome all the complexities involved in prior available methods for transportation of radiopharmaceutical imaging systems or medical radioisotope elution systems.

Abstract: A radioisotope elution system is provided. The radioisotope elution system may comprise a controller that is configured to calculate the available amount of daughter radioisotope at any time during establishment of the equilibrium for decay of the parent radioisotope into its daughter radioisotope. The radioisotope elution system may comprise a controller that is configured to schedule various patient infusions planned for the next following days and weeks in accordance with the available amount of daughter radioisotope on each day. The elution system may also comprise a controller that is connected to the imaging software of a radioisotope imaging device, where the radioisotope imaging device is arranged for imaging the patient or a region of the patient; and the controller is configured to start an image acquisition at a predetermined time.

Abstract: The present invention provides a method of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease via Positron Emitting Tomography (PET) imaging technology. The method comprises administering a PET radionuclide into the subject via automated generation and/or infusion system, performing PET scan of the region of interest, automated assessment of the PET images, performing assessment and suggesting the most appropriate therapeutic and/or management options for the patients based on the severity score, provides an assessment of regional lower proximity perfusion and perfusion reserve, and/or regional and mean standardized uptake values (SUVs). More particularly, the method of image processing identifies the regional differences in SMP (Skeletal muscle perfusion) and SMPR (Skeletal muscle perfusion reserve) across calf muscles at rest and cuff-induced hyperemia.